482 related articles for article (PubMed ID: 18977255)
1. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
4. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.
Youn YS; Chae SY; Lee S; Kwon MJ; Shin HJ; Lee KC
Eur J Pharm Biopharm; 2008 Mar; 68(3):667-75. PubMed ID: 17904340
[TBL] [Abstract][Full Text] [Related]
5. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
[TBL] [Abstract][Full Text] [Related]
6. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
Chae SY; Choi YG; Son S; Jung SY; Lee DS; Lee KC
J Control Release; 2010 May; 144(1):10-6. PubMed ID: 20093159
[TBL] [Abstract][Full Text] [Related]
7. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Son S; Chae SY; Kim CW; Choi YG; Jung SY; Lee S; Lee KC
J Med Chem; 2009 Nov; 52(21):6889-96. PubMed ID: 19827752
[TBL] [Abstract][Full Text] [Related]
8. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
13. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.
Lee S; Youn YS; Lee SH; Byun Y; Lee KC
Diabetologia; 2006 Jul; 49(7):1608-11. PubMed ID: 16586064
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
16. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
[TBL] [Abstract][Full Text] [Related]
17. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.
Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T
Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961
[TBL] [Abstract][Full Text] [Related]
18. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
Barakat GM; Nuwayri-Salti N; Kadi LN; Bitar KM; Al-Jaroudi WA; Bikhazi AB
Gen Physiol Biophys; 2011 Mar; 30(1):34-44. PubMed ID: 21460410
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
Park S; Hong SM; Sung SR
Life Sci; 2008 Feb; 82(9-10):503-11. PubMed ID: 18237751
[TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
